Back to search
GERD - PPI Non-responders
Clinical trial pipeline · Data from ClinicalTrials.gov
See which GERD - PPI Non-responders trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which GERD - PPI Non-responders trials you may qualify forGastroesophageal reflux disease (GERD) is a very common condition affecting up to 30% of adults. To date, therapy consists of powerful acid suppression with pro…
The prevalence of GERD is estimated to be as high as 20% in the US, and up to 50% remain symptomatic on proton pump inhibitor (PPI) therapy. The clinical approa…
Gastroesophageal reflux disease (GERD) is a common chronic condition, affecting approximately 20% of the American adult population. Proton pump inhibitors (PPIs…